rhuIL-2 adjunctive therapy in multidrug resistant tuberculosis: A comparison of two treatment regimens and placebo

Simple item page
dc.contributor.authorJohnson B.J.
dc.contributor.authorBekker L.-G.
dc.contributor.authorRickman R.
dc.contributor.authorBrown S.
dc.contributor.authorLesser M.
dc.contributor.authorRess S.
dc.contributor.authorWillcox P.
dc.contributor.authorSteyn L.
dc.contributor.authorKaplan G.
dc.date.accessioned2011-05-15T16:18:17Z
dc.date.available2011-05-15T16:18:17Z
dc.date.issued1997
dc.description.abstractSetting: Low-dose recombinant human interleukin 2 (rhuIL-2) adjunctive immunotherapy in multidrug resistant tuberculosis (MDR-TB) patients. Objective: Evaluation of the effects of daily versus pulse-administered rhuIL-2 compared to placebo. Design: MDR-TB patients on best available antituberculous chemotherapy received rhuIL-2 for 30 consecutive days (daily therapy), or for 5 days followed by a 9-day 'rest', for three cycles (pulse therapy). Placebo control patients received diluent. The cumulative total dose of rhuIL-2 given to each patient in either rhuIL-2 treatment group was the same. Patient immunologic, microbiologic, and radiologic responses were compared. Results: The three treatment schedules induced different results. Immune activation was documented in patients receiving daily rhuIL-2 therapy. Numbers of CD25+ and CD56+ cells in the peripheral blood were increased in these patients, but not in patients receiving pulse rhuIL-2 or placebo. In addition, 5/8 (62%) patients receiving daily rhuIL-2 demonstrated reduced or cleared sputum bacterial load while only 2/7 (28%) pulse rhuIL-2 treated and 2/8 (25%) controls showed bacillary clearance. Chest radiographs of 7/12 (58%) patients receiving daily rhuIL-2 indicated significant improvement over 6 weeks. Only 2/9 (22%) pulse rhuIL-2-treated patients and 5/12 (42%) placebo controls showed radiologic improvement. Conclusion: Daily low dose rhuIL-2 adjunctive treatment stimulates immune activation and may enhance the antimicrobial response in MDR-TB.
dc.description.versionArticle
dc.identifier.citationTubercle and Lung Disease
dc.identifier.citation78
dc.identifier.citation3-4
dc.identifier.issn09628479
dc.identifier.other10.1016/S0962-8479(97)90026-5
dc.identifier.urihttp://hdl.handle.net/10019.1/14594
dc.subjectcd56 antigen
dc.subjectclofazimine
dc.subjectethambutol
dc.subjectethionamide
dc.subjectinterleukin 2 receptor
dc.subjectisoniazid
dc.subjectkanamycin
dc.subjectofloxacin
dc.subjectpyrazinamide
dc.subjectrecombinant interleukin 2
dc.subjectrifabutin
dc.subjectrifampicin
dc.subjectstreptomycin
dc.subjectterizidone
dc.subjectthioacetazone
dc.subjectadult
dc.subjectarticle
dc.subjectbacterial count
dc.subjectclinical article
dc.subjectclinical trial
dc.subjectcontrolled study
dc.subjectdrug efficacy
dc.subjectfemale
dc.subjecthuman
dc.subjectimmunostimulation
dc.subjectintradermal drug administration
dc.subjectmale
dc.subjectmultidrug resistance
dc.subjectpriority journal
dc.subjectsputum culture
dc.subjectthorax radiography
dc.subjecttreatment outcome
dc.subjecttuberculosis
dc.subjectAdult
dc.subjectAntigens, CD56
dc.subjectAntitubercular Agents
dc.subjectChemotherapy, Adjuvant
dc.subjectDrug Administration Schedule
dc.subjectFemale
dc.subjectHumans
dc.subjectImmunophenotyping
dc.subjectInterleukin-2
dc.subjectLung
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectReceptors, Interleukin-2
dc.subjectRecombinant Proteins
dc.subjectSputum
dc.subjectTuberculosis, Multidrug-Resistant
dc.titlerhuIL-2 adjunctive therapy in multidrug resistant tuberculosis: A comparison of two treatment regimens and placebo
dc.typeArticle
Files
Collections
Stellenbosch University - Scopus Tygerberg Hospital Publications